论文部分内容阅读
目的 观察长春瑞滨(Vinorelbine,商品名:盖诺)加奥沙利铂(Oxaliplatin,商品名:艾恒)联合化疗治疗晚期非小细胞肺癌(NSCLC)的临床效果和毒副反应。方法 26例晚期非小细胞肺癌患者采用盖诺25 mg/m2静脉推注,第1、8天;艾恒.130 mg/m2,静脉滴注4 h,第1天,21-28 d重复。结果 全组部分缓解(PR)9例,稳定(SD)12例,进展(PD)5例,总有效率(RR)为34.6％。主要毒副反应为骨髓抑制(Ⅲ-Ⅳ度白细胞减少发生率为42.3％)、神经毒性(80.8％)及恶心呕吐(42.3％)等。结论 长春瑞滨加奥沙利铂联合化疗方案治疗晚期非小细胞肺癌的疗效较高,耐受性好,值得临床进一步研究。
Objective To observe the clinical effects and side effects of Vinorelbine combined with oxaliplatin and chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). Methods 26 patients with advanced non-small cell lung cancer were treated with intravenous injection of Ginorzine 25 mg / m 2 on days 1 and 8, and Aiheng 130 mg / m 2 intravenously for 4 h. The first day and the second 21-28 d were repeated. Results The total partial response (PR) in 9 cases, stable (SD) in 12 cases, progression (PD) in 5 cases, the total effective rate (RR) was 34.6%. The main toxicities were myelosuppression (grade Ⅲ-Ⅳ leukopenia was 42.3%), neurotoxicity (80.8%) and nausea and vomiting (42.3%). Conclusion The combination of vinorelbine and oxaliplatin combined with chemotherapy in the treatment of advanced non-small cell lung cancer is more effective and tolerable and deserves clinical further study.